SCRI Development Innovations, LLC

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

Phase 2

Terminated

Conditions: Urothelial Carcinoma
Bladder Cancer
Transitional Cell Carcinoma

Interventions: Drug: nab-paclitaxel
Drug: Gemcitabine

First Posted Date: 2016-09-02

Last Posted Date: 2023-12-05

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 3

Registration Number: NCT02887248

Locations: 🇺🇸
Center for Cancer and Blood Disorders, Fort Worth, Texas, United States
🇺🇸
Florida Cancer Specialists-North, Saint Petersburg, Florida, United States
🇺🇸
Florida Cancer Specialists - South, Fort Myers, Florida, United States

and more 2 locations

Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

Phase 2

Terminated

Conditions: Carcinoid Tumors
Gastrointestinal Neoplasms
Neuroendocrine Tumors

Interventions: Drug: Lanreotide
Device: Y-90 microspheres

First Posted Date: 2016-08-08

Last Posted Date: 2023-12-05

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 6

Registration Number: NCT02859064

Locations: 🇺🇸
Tennessee Oncology PLLC, Nashville, Tennessee, United States
🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸
Research Medical Center/HCA Midwest, Kansas City, Missouri, United States

Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: elotuzumab
Drug: Lenalidomide
Drug: Dexamethasone
Procedure: autologous stem cell transplantation

First Posted Date: 2016-07-25

Last Posted Date: 2023-12-05

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 53

Registration Number: NCT02843074

Locations: 🇺🇸
HCA Midwest Health/Research Medical Center, Kansas City, Missouri, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
Nebraska Methodist Hospital, Omaha, Nebraska, United States

and more 2 locations

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Phase 2

Completed

Conditions: Urothelial Carcinoma
Gastrointestinal Carcinoma, Non-colon
Upper Aerodigestive Tract Carcinoma
Non-small Cell Lung Carcinoma

Interventions: Drug: Afatinib
Drug: Regorafenib
Drug: Cabozantinib

First Posted Date: 2016-06-09

Last Posted Date: 2023-12-05

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 100

Registration Number: NCT02795156

Locations: 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
Florida Cancer Specialists - South, Fort Myers, Florida, United States
🇺🇸
Florida Cancer Specialists - East, West Palm Beach, Florida, United States

and more 5 locations

LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies

Phase 1

Terminated

Conditions: Small Cell Lung Cancer
Ovarian Cancer

Interventions: Drug: LCL161
Drug: Topotecan
Drug: Pegylated GCSF (PEG-GCSF)

First Posted Date: 2016-01-07

Last Posted Date: 2023-12-05

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 34

Registration Number: NCT02649673

Locations: 🇺🇸
Florida Cancer Specialists-Sarasota, Sarasota, Florida, United States
🇺🇸
Oklahoma University Health Science Center/Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
🇺🇸
Tennessee Oncology PLLC, Nashville, Tennessee, United States

Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBC

Completed

Conditions: Metastatic Breast Cancer

First Posted Date: 2015-05-07

Last Posted Date: 2020-09-02

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 74

Registration Number: NCT02436772

Locations: 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States

iCORE: Collaborative Orthopedics Outcomes Registry

Withdrawn

Conditions: Arthroplasty, Replacement, Hip
Arthroplasty, Replacement, Knee

First Posted Date: 2015-04-21

Last Posted Date: 2023-12-05

Lead Sponsor: SCRI Development Innovations, LLC

Registration Number: NCT02422667

Locations: 🇺🇸
SCRI, Nashville, Tennessee, United States

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

Phase 1

Completed

Conditions: Glioblastoma Multiforme
Colorectal Cancer
Gliosarcoma
Renal Cell Carcinoma

Interventions: Drug: INC280
Biological: bevacizumab

First Posted Date: 2015-03-12

Last Posted Date: 2023-09-21

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 65

Registration Number: NCT02386826

Locations: 🇺🇸
HCA Midwest - Kansas City, Kansas City, Missouri, United States
🇺🇸
Oklahoma University Health Science Center, Oklahoma City, Oklahoma, United States
🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States

and more 2 locations

Sarah Cannon Outcomes Registry

Withdrawn

Conditions: Oncology

First Posted Date: 2015-02-05

Last Posted Date: 2023-12-05

Lead Sponsor: SCRI Development Innovations, LLC

Registration Number: NCT02356822

Locations: 🇺🇸
SCRI, Nashville, Tennessee, United States

Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers

Phase 2

Completed

Conditions: Neuroendocrine Cancer

Interventions: Drug: Carfilzomib

First Posted Date: 2014-12-17

Last Posted Date: 2023-12-05

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 62

Registration Number: NCT02318784

Locations: 🇺🇸
Oncology Hematology Care, INC., Cincinnati, Ohio, United States
🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸
Florida Cancer Specialists - North, Saint Petersburg, Florida, United States

and more 7 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy